BioAge Labs, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
BioAge dosed first participant in QUELL-CV (Phase 2, ~160 patients, obesity+inflammation, three doses: 30/60/90 mg vs. placebo) in June 2026, with topline data expected H2 2026. QUELL-DME Phase 1b/2a trial planned mid-2026 in diabetic macular edema, data mid-2027. Q2 2026 net loss $26.1M vs. $21.6M YoY; R&D expenses $24.4M (+$4.6M, driven by BGE-102 clinical costs). Cash position $381.3M; runway extended through 2029.
Why this rating
Phase 2 initiation is clinical progress, but early-stage biotech milestone; no efficacy/safety surprise yet. Cash runway strong relative to 339% market cap burn rate. Moderate for $112.7M company.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.